Answers are grounded in this paper and cite their sources.
Proof-of-concept study demonstrates that sequential DAC and entinostat treatment sensitizes cancer cells via inducible SALL4, suggesting a strategy for tumors lacking conventional targets.
. Moreover, SALL4 was essential for the efficiency of sequential treatment of DAC and entinostat. Overall, this proof-of-concept study provides a framework whereby the targeting pathways such as SALL4-centered therapy can be expanded, sensitizing cancer cells to treatment by transient target induction and engineering a dependency. SIGNIFICANCE: These findings provide a therapeutic approach for patients harboring no suitable target by induction of a SALL4-mediated vulnerability.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: